Drug Approval | February 24, 2023
SERDA therapeutics submits IND for wound debridement agent
Clinical studies are expected to start in Q2 2023.
Clinical studies are expected to start in Q2 2023.
Famotidine Injection is indicated to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
Wearable patch sensors (smart patches) are rising in popularity, as they offer a wide range of options for medical diagnosis
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
With this move, government hospitals across India can now access the geko device to prevent life-threatening blood clots, and address complications related to swelling following orthopaedic surgery and the healing of chronic wounds (leg ulcers)
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
In 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by diabetes, as per WHO
Next-generation radiofrequency catheter offers first thermal ablation perforator treatment advancement in over 10 years
Subscribe To Our Newsletter & Stay Updated
